CN100384458C - Liver beneficial pharmaceutical composition and method for preparing the same - Google Patents
Liver beneficial pharmaceutical composition and method for preparing the same Download PDFInfo
- Publication number
- CN100384458C CN100384458C CNB2005102007379A CN200510200737A CN100384458C CN 100384458 C CN100384458 C CN 100384458C CN B2005102007379 A CNB2005102007379 A CN B2005102007379A CN 200510200737 A CN200510200737 A CN 200510200737A CN 100384458 C CN100384458 C CN 100384458C
- Authority
- CN
- China
- Prior art keywords
- parts
- liver
- pharmaceutical composition
- beneficial pharmaceutical
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The present invention relates to a Gaoligankang medicinal composition containing ginseng, perilla seed oil, duck meat, etc. The production method of the present invention comprises the following steps: a required amount of ginseng, etc. is crushed into fine powder; a required amount of duck meat is minced and added with a required amount of perilla seed oil; the minced duck meat with perilla seed oil and the fine power are mixed with each other, stewed at medium baking temperature, dried at low temperature and crushed to obtain medicinal powder; the rest medicines, such as white peony alba, etc., are processed by aqueous extract, concentrated to extract and are evenly mixed with the medicinal powder to obtain semi-finished product. The present invention has the following functions and main curative effect: supporting the healthy energy, stretching the liver, regulating vital energy, nourishing blood and Yin, invigorating the stomach and the spleen, effectively curing chronic hepatitis, such as virus hepatitis, liver ascites, alcoholic livers, fatty livers, hepatic cirrhosis, etc., reducing fat in the liver and blood, maintaining hepatic function, reinforcing the microcirculation of liver blood flow and the parenchymatous of the liver, decreasing blood stasis of organs, accelerating the blood flow rate of the liver, preventing the development of the chronic fibrosis of the liver, decelerating the fibrosis process and promoting liver cell regeneration. The present invention has the advantages that the production method is easy to implement, and the cost is lower.
Description
Technical field
The present invention relates to composite medicine and production method thereof, is a kind of Koryo liver beneficial pharmaceutical composition and production method thereof, is applicable to chronic hepatitiss such as treatment viral hepatitis, hepatic ascites, alcoholic liver, fatty liver, liver cirrhosis.
Background technology
Chronic hepatitis social and have very high epidemic rate determines its importance in epidemiology.It can make patient lose work capacity for a long time, disable, and mortality rate is very high.For many years, these indexs all show a rising trend.Whole world hepatopath has surpassed 400,000,000 people at present, and hepatopathy is one of disease that has a strong impact on human health.
Chronic hepatitis is divided into by source of disease: autoimmune type hepatitis, chronic hepatitis B, the third type chronic hepatitis, fourth type chronic hepatitis, chronic viral hepatitis (other is not classified), chronic hepatitis (atypical doubtful viral or doubtful autoimmunity), chronic drug induced hepatitis, primary liver cirrhosis, constitutional sclerosis biliary tract inflammation, tie up low great mansion buffalo gnat tail 1. bosom Pu bright over sixty years of age of the Dried-meat-1 A Pu Te Linsen of the committee hepatopathys of sharp Bu mother-in-law Song, be divided into by active degree: slight, faint reflection, the moderate reflection, reflection is divided into by the stage: no fiber, slight (portal vein) fiber, serious fibrosis.
So far, at home and abroad there is no the satisfied specific medicament that is used for the treatment of chronic hepatitis.Although Chinese medicine draw in theory ancient opinion modern, manage out certificate, dialectical complicated and changeable, and can't form unifiedly to the diagnostic criteria of chronic hepatitis and fixing prescription, therefore the therapeutic effect to chronic hepatitis is difficult to be affirmed by the world.No matter modern medicine is the molecular biotechnology level of etiological diagnosis, and still high-tech imaging diagnosis means have all reached quite advanced level.Although it is existing many at the kind of the antiviral drugs of chronic hepatitis, but, thereby form drug resistance or reduced its curative effect, and because the toxic and side effects of antiviral drugs owing to the virus of chronic hepatitis easily morphs, therefore, the antiviral drugs of still not having ideal treatment chronic hepatitis so far.Simultaneously, for chronic hepatitis, Chinese medicine and modern medicine at present all can not be satisfactory at clinical therapeutic outcome, and the medical expense costliness also causes most patient to be difficult to bear.The intractable medical circle question of common concern that become of chronic hepatitis.
Summary of the invention
The invention provides a kind of Koryo liver beneficial pharmaceutical composition and production method thereof, it can strengthening the body resistance, liver-smoothing, qi-regulating, nourishing the blood and yin, be good for the stomach and spleen, is applicable to chronic hepatitiss such as treatment viral hepatitis, hepatic ascites, alcoholic liver, fatty liver, liver cirrhosis
One of technical scheme of the present invention is achieved like this: a kind of Koryo liver beneficial pharmaceutical composition, contain 8 parts to 10 parts of Radix Ginsengs, 10 parts to 14 parts of the Radix Paeoniae Albas, 10 parts to 14 parts of NINGQI, 7 parts to 8 parts of Rhizoma Chuanxiongs, 7 parts to 8 parts of Rhizoma Cyperis, 16 parts to 33 parts of Fructus Perillae oil, 22 parts to 28 parts of mushrooms, 8 parts to 10 parts of semen juglandiss, 8 parts to 12 parts of Ovum Gallus domesticus Flavuss, 220 parts to 280 parts of duck meats, 2 parts to 5 parts in Radix Glycyrrhizae by parts by weight of raw materials.
This Koryo liver beneficial pharmaceutical composition that is used for the treatment of chronic hepatitis contains 9 parts of Radix Ginsengs, 11 parts of the Radix Paeoniae Albas, 13 parts of NINGQI, 8 parts of Rhizoma Chuanxiongs, 8 parts of Rhizoma Cyperis, 31 parts of Fructus Perillae oil, 28 parts of mushrooms, 9 parts of semen juglandiss, 10 parts of Ovum Gallus domesticus Flavuss, 260 parts of duck meats, 3 parts in Radix Glycyrrhizae by parts by weight of raw materials the best.
Two of technical scheme of the present invention is achieved like this: the production method of above-mentioned Koryo liver beneficial pharmaceutical composition is undertaken by following step: at first Radix Ginseng, Rhizoma Cyperi, semen juglandis, the Ovum Gallus domesticus Flavus with requirement is ground into fine powder, the duck meat of requirement is rubbed, the Fructus Perillae oil that adds requirement, mix with above-mentioned fine powder, place jar, add a cover water proof with moderate heat stew open in water after 0.5 hour to 2 hours, cold drying and pulverize and obtain medicated powder then; All the other Radix Paeoniae Albas, NINGQI, Rhizoma Chuanxiong, mushroom, each medicinal water extraction of Radix Glycyrrhizae 3 times are filtered, and filtrate is condensed into the extractum that relative density is 1.32-1.34, at last extractum and above-mentioned medicated powder mixing is obtained Koryo liver beneficial pharmaceutical composition semi-finished product.
Can be as required with Koryo liver beneficial pharmaceutical composition semi-finished product corning or make powder and obtain Koryo liver beneficial pharmaceutical composition finished product.
The function of Koryo of the present invention liver beneficial pharmaceutical composition with cure mainly: strengthening the body resistance, liver-smoothing, qi-regulating, nourishing the blood and yin is good for the stomach and spleen; It can treat chronic hepatitiss such as viral hepatitis, hepatic ascites, alcoholic liver, fatty liver, liver cirrhosis effectively, and can reduce fat in liver and the blood, play the effect of maintenance liver, and can strengthen the microcirculation of liver blood stream regulating liver-QI parenchyma, reduce internal organs congestion, accelerate liver blood flow speed, the development of prevention liver chronic fibrosis slows down the fibrosis process, promotes liver cell regeneration, its production method is easy to realize that cost is relatively low.
The specific embodiment
The present invention is not subjected to the restriction of following embodiment, can determine concrete embodiment according to the technical scheme and the practical situation of the invention described above.
Embodiment 1, and this Koryo liver beneficial pharmaceutical composition contains 8 parts of Radix Ginsengs, 10 parts of the Radix Paeoniae Albas, 10 parts of NINGQI, 7 parts of Rhizoma Chuanxiongs, 7 parts of Rhizoma Cyperis, 16 parts of Fructus Perillae oil, 22 parts of mushrooms, 8 parts of semen juglandiss, 8 parts of Ovum Gallus domesticus Flavuss, 220 parts of duck meats, 2 parts in Radix Glycyrrhizae by parts by weight of raw materials.
Embodiment 2, and this Koryo liver beneficial pharmaceutical composition contains 10 parts of Radix Ginsengs, 14 parts of the Radix Paeoniae Albas, 14 parts of NINGQI, 8 parts of Rhizoma Chuanxiongs, 8 parts of Rhizoma Cyperis, 33 parts of Fructus Perillae oil, 28 parts of mushrooms, 10 parts of semen juglandiss, 12 parts of Ovum Gallus domesticus Flavuss, 280 parts of duck meats, 5 parts in Radix Glycyrrhizae by parts by weight of raw materials.
Embodiment 3, and this Koryo liver beneficial pharmaceutical composition contains 8 parts of Radix Ginsengs, 14 parts of the Radix Paeoniae Albas, 10 parts of NINGQI, 8 parts of Rhizoma Chuanxiongs, 7 parts of Rhizoma Cyperis, 33 parts of Fructus Perillae oil, 22 parts of mushrooms, 10 parts of semen juglandiss, 8 parts of Ovum Gallus domesticus Flavuss, 280 parts of duck meats, 2 parts in Radix Glycyrrhizae by parts by weight of raw materials.
Embodiment 4, and this Koryo liver beneficial pharmaceutical composition contains 10 parts of Radix Ginsengs, 10 parts of the Radix Paeoniae Albas, 14 parts of NINGQI, 7 parts of Rhizoma Chuanxiongs, 8 parts of Rhizoma Cyperis, 16 parts of Fructus Perillae oil, 28 parts of mushrooms, 8 parts of semen juglandiss, 12 parts of Ovum Gallus domesticus Flavuss, 220 parts of duck meats, 5 parts in Radix Glycyrrhizae by parts by weight of raw materials.
Embodiment 5, and this Koryo liver beneficial pharmaceutical composition contains 8 parts of Radix Ginsengs, 10 parts of the Radix Paeoniae Albas, 10 parts of NINGQI, 7 parts of Rhizoma Chuanxiongs, 7 parts of Rhizoma Cyperis, 33 parts of Fructus Perillae oil, 28 parts of mushrooms, 10 parts of semen juglandiss, 12 parts of Ovum Gallus domesticus Flavuss, 280 parts of duck meats, 5 parts in Radix Glycyrrhizae by parts by weight of raw materials.
Embodiment 6, and this Koryo liver beneficial pharmaceutical composition contains 10 parts of Radix Ginsengs, 14 parts of the Radix Paeoniae Albas, 14 parts of NINGQI, 8 parts of Rhizoma Chuanxiongs, 8 parts of Rhizoma Cyperis, 16 parts of Fructus Perillae oil, 22 parts of mushrooms, 8 parts of semen juglandiss, 8 parts of Ovum Gallus domesticus Flavuss, 220 parts of duck meats, 2 parts in Radix Glycyrrhizae by parts by weight of raw materials.
Embodiment 7, and this Koryo liver beneficial pharmaceutical composition contains 8 parts of Radix Ginsengs, 10 parts of the Radix Paeoniae Albas, 14 parts of NINGQI, 8 parts of Rhizoma Chuanxiongs, 7 parts of Rhizoma Cyperis, 16 parts of Fructus Perillae oil, 28 parts of mushrooms, 10 parts of semen juglandiss, 8 parts of Ovum Gallus domesticus Flavuss, 220 parts of duck meats, 5 parts in Radix Glycyrrhizae by parts by weight of raw materials.
Embodiment 8, and this Koryo liver beneficial pharmaceutical composition contains 10 parts of Radix Ginsengs, 14 parts of the Radix Paeoniae Albas, 10 parts of NINGQI, 7 parts of Rhizoma Chuanxiongs, 8 parts of Rhizoma Cyperis, 33 parts of Fructus Perillae oil, 22 parts of mushrooms, 8 parts of semen juglandiss, 12 parts of Ovum Gallus domesticus Flavuss, 280 parts of duck meats, 2 parts in Radix Glycyrrhizae by parts by weight of raw materials.
Embodiment 9, and this Koryo liver beneficial pharmaceutical composition contains 9 parts of Radix Ginsengs, 11 parts of the Radix Paeoniae Albas, 13 parts of NINGQI, 8 parts of Rhizoma Chuanxiongs, 8 parts of Rhizoma Cyperis, 31 parts of Fructus Perillae oil, 28 parts of mushrooms, 9 parts of semen juglandiss, 10 parts of Ovum Gallus domesticus Flavuss, 260 parts of duck meats, 3 parts in Radix Glycyrrhizae by parts by weight of raw materials.
Koryo liver beneficial pharmaceutical composition in the foregoing description can obtain by following production method: at first Radix Ginseng, Rhizoma Cyperi, semen juglandis, the Ovum Gallus domesticus Flavus with requirement is ground into fine powder, the duck meat of requirement is rubbed, the Fructus Perillae oil that adds requirement, mix with above-mentioned fine powder, place jar, add a cover water proof with moderate heat stew open in water after 0.5 hour or 1 hour or 1.5 hours or 2 hours, under existing Chinese patent medicine cold drying technology, carry out then drying also pulverizing obtain medicated powder; The water of all the other Radix Paeoniae Albas, NINGQI, Rhizoma Chuanxiong, mushroom, each medicinal existing Chinese patent medicine of Radix Glycyrrhizae is put forward technology and is extracted 3 times, filter, filtrate is condensed into the extractum that relative density is 1.32-1.34, at last extractum and above-mentioned medicated powder mixing is obtained Koryo liver beneficial pharmaceutical composition semi-finished product.And can be as required with Koryo liver beneficial pharmaceutical composition semi-finished product corning or make powder and obtain Koryo liver beneficial pharmaceutical composition finished product.
Koryo of the present invention liver beneficial pharmaceutical composition also can obtain according to the production method of existing Chinese patent medicine technology.
The foregoing description products obtained therefrom is that the therapeutic effect of Koryo liver beneficial pharmaceutical composition is as follows:
The instructions of taking of Koryo of the present invention liver beneficial pharmaceutical composition:
First week: 3 times on the one, one time 1 bag, every bag weigh 9 grams, and 20 minutes ante cibum with under a large amount of warm water clothes (drinking water) more; After second week reached: stipulate 3 times on the one, one time 2 bag, 20 minutes ante cibum are with a large amount of warm water clothes down.
One, the ultrasound wave that is used for the treatment of the chronic hepatitis patient is followed the tracks of detection: two months course of treatment.
5 male's Patients with Viral Hepatitis have been investigated (wherein, 3 Cases with Viral Hepatitis C by name, 2 hepatitis B patients by name), at the process antiviral therapy, and after repeatedly confirming to still have the result of virus existence, just decision uses Koryo of the present invention liver beneficial pharmaceutical composition to treat.Experimental analysis equipment: SONO-Ace6000C (Mai Jisong company, Korea S) (have pulse-fluctuation and color Doppler draw to flow sensor).Follow-up investigations are to carry out in during using two months of Koryo of the present invention liver beneficial pharmaceutical composition treatment.Its content comprises: detect liver size and portal vein, portal venous flow and liver parenchyma echo.
1, before the treatment of use Koryo of the present invention liver beneficial pharmaceutical composition, the testing result of indexs such as patient's ultrasound wave sees following table for details
| Liver: right liver | 168.9mm (standard＜140mm) | 20.6％ |
| Left side liver | 103.1mm (standard＜90mm) | 12.5％ |
| The right branch of portal vein arteries and veins | 14mm (standard＜12mm) | 12.5％ |
| Liver parenchyma density | 37 units (standard＜16 units) | 131％ |
| Portal venous flow | 92/43mm (standard＜400/200mm/ second) | 23/21.5％ |
| The spleen area | 55.9 square centimeter (standard＜50 square centimeter) | 11.8％ |
| Bilirubin | 24.6mM/L (standard＜20mM/L) | 23％ |
| Transaminase ALT | (0.95 standard＜0.77) | 35.7％ |
| Transaminase ACT | (0.41 standard＜0.35) | 17.1％ |
| GGT | 32 grams per liters (standard＜37) | Normally |
As above show the data of ultrasound detection, all patients' liver increases more than 30%, and it is round blunt that the lower edge of liver becomes, and liver parenchyma echo is by suitably increasing to very big, and 23% is unclear because of the fibrous lesions profile, and heterogeneous section is arranged.Liver parenchyma density fluctuates between 36-54 unit.Detect with color Doppler figure instrument, can see that patient's vascular profile of 44% loses nutrition, the portal vein blood flow rate is reduced to 92/43mm/ second.The ultrasonic figure of chronic hepatitis: because of the fibrous lesions section is arranged, liver density improves in various degree, and the right branch of portal vein arteries and veins enlarges 14mm.Liver parenchyma density improves 37 units (standard is less than 16 units).The third type chronic hepatitis patient door blood flow rate is reduced to 96/6mm/ second.
2, the dynamic indicator of the ultrasonic test of the treatment chronic hepatitis behind the liver beneficial pharmaceutical composition of use Koryo of the present invention detects, and sees following table for details:
As above show listedly, after 2 weeks, obtain following effect from begin treatment: clinical feel obvious improvement 3 people (in 5 patients) are arranged; The RHC pain relief 4 people (among 5 patients) are arranged; What RHC did not have a sense of heaviness has 3 people (among 5 patients); Feeling of fatigue alleviates 5 patients.
Treat the detection data after 2 weeks: transaminase ALT and ACT level descend, and are respectively 14.2% and 21.4%; Bilirubin level drops to normally; The ultrasonic examination data: the liver size decreases is to normal, right portal vein offshoot size decreases 5.8%; Improving blood flow 27/16%; Liver parenchyma density is reduced to 23 units;
From begin treatment 1 month, to obtaining following result in the dynamic observing of patient: clinically feel obvious improvement one all 5 patients; There are 4 among RHC pain relief-5 patient; RHC does not have there are 4 among sense of heaviness-5 patient; Feeling of fatigue alleviates all 5 patients.Treat 1 month detection data: transaminase ALT and ACT level descend, respectively to 0.85% and 0.35%; The ultrasonic examination data: the liver size is contracted to normally; Portal vein offshoot size is decreased to normally; Is the blood flow index improved? 34/50%, the arteriopalmus blood flow has normal feature, seldom changes because of respiratory movement; Elbow parenchyma density is reduced to 18.75; With color Doppler figure instrument inspection door system, gapped property is replenished disappearance, and this is the feature of door system fiber change degree just.
Treated for 4 weeks, door blood flow index improves 34/50%; Liver parenchyma density is reduced to 18.75%.
From beginning to take Koryo liver beneficial pharmaceutical composition treatment after 2 months, observe very stable therapeutic effect.The speed that has kept the liver size to dwindle, its parenchyma density reduces, the blood capillary of the visible liver of vision; Clinical feel to improve reach 100%; The liver size has changeed little 100%; The RHC pain relief 100%; Feeling of fatigue has alleviated 100%.
Treat and detected data in 2 months: transaminase ALT and ACT level drop to normally; Bilirubin level drops to normally; Treat 2 months ultrasound detection data: the liver size is contracted to normally; The blood flow index is improved to 220/53mm/ second; Liver parenchyma density is reduced to normally; Portal vein diameter reduces, and has improved blood flow rate, has reduced the blood flow rate index.
Conclusion: follow the tracks of the PRELIMINARY RESULTS of investigating the chronic hepatitis patient and show, Koryo of the present invention liver beneficial pharmaceutical composition has actual effect: improve blood flow trend, promote the hepatocyte recovering process, reduce hepatic fibrosis, reduce liver parenchyma density, improve liver function and strengthen the elasticity of liver.
Two, the ultrasound wave that is used for the treatment of fatty liver tumor people is followed the tracks of detection: two months course of treatment.
Follow the tracks of to investigate 7 fatty liver tumor people, wherein 4 men, 3 woman suffer from livers fat and lose and support disease (age 40-53 year).7 all overweight 20-30% of patient have obesity in various degree.In 3 people's medical history, once suffered from hepatitis A.All patients all feel RHC heavy, swell, pain, weakness, easily tired, fat foods can not consume oil.To the indexs such as cytoactive, transaminase, alkali phosphatase, bilirubin, cholesterol and triglyceride of all the hepatitis diseases chamber assay (except B-mode, third type and the hepatitis D) that experimentizes.
Check with equipment to be SONO-Ace6000C (Korea S, Mai Jisong company), be have the frequency that floats, impulse wave and colorful general rein in instrument to flow sensor.Ultrasonic comprehensive detection comprises: use before the liver beneficial pharmaceutical composition of Koryo of the present invention and patient liver size, echo, the assessment of liver outer rim, portal venous flow etc. during the treatment after 2 months.
1, before the treatment of use Koryo of the present invention liver beneficial pharmaceutical composition, the testing result of indexs such as patient's ultrasound wave, see following table for details:
| Liver: right liver | 168mm | 20％ |
| Liver: left liver | 90mm | The normal value upper limit |
| Liver parenchyma density | 34 | 70％ |
| Portal venous flow | 10/6cm/second | 25-30％ |
| Bilirubin | 22.3mm/L | 8.9％ |
| Transaminase ALT | 0.69 | The normal value upper limit |
| Transaminase ACT | 0.38 | 8.5％ |
| Cholesterol | 8.5 | 23.5％ |
| Triglyceride | ?2 | Normal value |
The liver density of fat hepatoma is by faint one 35 units of ultrasonoscopy of rear arc background.Fatty liver tumor people's door blood flow Doppler image: blood flow rate is reduced to 10/6cm/ second (normal value is 32-40cm/ second).
2, take the testing result of the index such as ultrasonic during the liver beneficial pharmaceutical composition of Koryo of the present invention, see following table for details:
As above show listedly, after 2 weeks, obtain following effect: clinically feel obvious improvement 71.5% from begin treatment; RHC pain relief 85.7%; There is not tired out sense 71.4%.Lose weight 57.1%.2 week of treatment back detection data: transaminase ALT and ACT level drop to normally; Cholesterol descends 23%; Bilirubin level drops to normally; Treatment 2 week back ultrasonic examination data: the liver size reduces 7.2% improving blood flow 180%; Liver parenchyma density reduces by 55%; Through the treatment of 2 weeks, liver cures mainly density and is reduced to 31 units.
Treat the effect after 1 month: clinically feel obvious improvement 100%; 87.5% of RHC pain relief; There is not 100% of tired out sense.Treat the detection data after 1 month: transaminase ALT and ACT level drop to normally; Cholesterol descends 10.7%.The ultrasonic examination data: the liver size is contracted to normally; The blood flow index improves 200%, and liver parenchyma density is reduced to normally.Treated for 4 weeks, door blood flow index improves 200%; Liver parenchyma density is reduced to normally;
Treat the effect after 2 months: clinical feeling improves 100%; It is little by 100% that the liver size is changeed; RHC pain relief 100%; There is not tired out sense 100%; Lose weight 100%; Treat 2 months detection data: transaminase ALT and ACT level drop to normally; Cholesterol is reduced to the normal value upper limit; Bilirubin level is reduced to normally; Treat 2 months ultrasound detection data: the liver size is contracted to normally; The blood flow index improves 330%; Liver parenchyma density is reduced to normally.
Conclusion: preliminary follow-up investigations show, use clinical, the laboratory of Koryo of the present invention liver beneficial pharmaceutical composition treatment hepatic lipoma patient demonstration and ultrasonic index that improvement is all arranged.In the treatment, feeling of patient is clearly better, weight loss 7-17 kilogram, and sensation is easily.When treatment finished, it was normal to detect index; Reexamine after two months, its every index is still in range of normal value; Liver size and liver parenchyma density return to range of normal value; Liver blood stream improves 350%.
Three, the ultrasound wave that is used for the treatment of fatty liver tumor people is followed the tracks of detection: two months course of treatment.
Follow the tracks of 19 patients in 2 liver cirrhosis patients and the monitoring group.Check with equipment to be SONO-Ace6000C (Korea S, Mai Jisong company), be have the frequency that floats, impulse wave and colorful general rein in instrument to flow sensor.
Reach in the treatment before taking Koryo of the present invention liver beneficial pharmaceutical composition, all carried out comprehensive ultrasound investigation.Comprise: check size right, left liver, structure echo, portal vein and offshoot size thereof; With ultrasonic-image of colorful Doppler instrument detecting gate venous blood flow, record intraperitoneal free fluid situation; Detect the size and the area of spleen.
To 19 patients of monitoring group, all carried out the inspection of liver, gallbladder system liver device echological picture.Observation is carried out under the B-state, and in the scope, it is even, clear that the profile of liver becomes at the fixed time.The front and back size of right liver is no more than 128mm (meansigma methods 114.4 ± 1.1), left liver 67mm (meansigma methods 65.2 ± 0.8); The long average 92.2 ± 1.06mm of spleen size, wide 65 ± 0.12mm, thick 38.6 ± 1.06mm, area is no more than 50cm
2, outer rim is even clear, and structure echo is identical.The observation portal vein, its diameter is 8-12mm (meansigma methods 10.3 ± 0.1).The how general image of Portal system vascular flow is decided by following index: portal venous flow 37.2-45.2cm/ second (meansigma methods 39.5 ± 1.7).Press BB, the blood vessel hierarchy is correct in the liver, and the hepatic vein vascular flow has three phase characters.The expansion of blood vessel is not obvious in the liver.
Certain patient, birth in 1956, private prosecution is very weak, easily tired, the right upper quadrant of the abdomen distending pain, digestive disorder, skin is itched once in a while.Diagnostic result: alcoholic cirrhosis is in time compensatory stage during prescription on individual diagnosis in 2004; Jaundice skin, liver cirrhosis.Hepatomegaly-be lower than rib camber line edge 2cm; Liver is solid-and the elastic region becomes circle, pain is arranged during percussion.Detect data: bilirubin 40mM/L, bilirubin direct-28mM/L, ALAT-0.84mM/L.
1, before the treatment of use Koryo of the present invention liver beneficial pharmaceutical composition, the testing result of indexs such as patient's ultrasound wave, see following table for details:
| Project name | Detect index | Alcoholic liver patient's index |
| The right liver of liver (front and back size) left side liver | 114±1.1 65.2±0.8 | 174 99 |
| Liver structure echo | Neatly, even | Irregular, echo group arranged |
| Liver echo | Echo is identical | Echo is improved |
| The liver blood vessel profile | Protected | Lack and support |
| The left branch of portal vein arteries and veins | 10.3±0.1 | 14.6 |
| Portal venous flow cm/ second | 39.5±1.7 | 16.1 |
| The spleen area | 750cm 2 | 60cm 2 |
| Spleen structure echo | Neatly, even | Neatly, even |
2, after the treatment of use Koryo of the present invention liver beneficial pharmaceutical composition, the testing result of indexs such as patient's ultrasound wave, see following table for details:
| Project name | Obey the preceding alcoholic cirrhosis of Koryo of the present invention liver beneficial pharmaceutical composition | Obey alcoholic cirrhosis behind the liver beneficial pharmaceutical composition of Koryo of the present invention |
| The right liver of liver (front and back size) left side liver | 174 99 | 169 75.6 |
| Liver structure echo | Irregular, echo group arranged | Irregular, echo group arranged |
| Liver echo | Echo is improved | Echo is improved |
| The liver blood vessel profile | Lack and support | Lack and support |
| The left branch of portal vein arteries and veins | 14.6 | 13 |
| Portal venous flow cm/ second | 16.1 | 20.1 |
| The spleen area | 60cm 2 | 56cm 2 |
| Spleen structure echo | Neatly, even | Neatly, even |
Patient A, life in 1936, the swelling of private prosecution abdominal part, weakness, edema of lower limbs, stomachache, xerostomia.Did hernia operations in 2002, be diagnosed as hepatitis C, ascites was arranged, promptly being diagnosed as liver cirrhosis at that time. clinical observation, liver are positioned at rib camber line edge, edema of lower limbs, xerosis cutis. laboratory data: bilirubin 24.640mM/L, bilirubin direct 102.mM/L
1, before the treatment of use Koryo of the present invention liver beneficial pharmaceutical composition, the testing result of indexs such as patient's ultrasound wave, see following table for details:
| Project name | Detect index | Viral liver cirrhosis |
| The right liver of liver (front and back size) left side liver | 114±1.1 65.2±0.8 | 132 87 |
| Liver structure echo | Neatly, even | Irregular, echo group arranged |
| Liver echo | Echo is improved | |
| The liver blood vessel profile | Protected | Lack and support |
| The right branch of portal vein arteries and veins | 10.3±0.1 | 11 |
| Portal venous flow cm/ second | 39.5±1.7 | 17.1 |
| The spleen area | 750cm 2 | 67cm 2 |
| Spleen structure echo | Neatly, even | Neatly, even |
| The abdominal cavity free liquid | Not secretion | Do not measure around liver, the spleen |
2, after the treatment of use Koryo of the present invention liver beneficial pharmaceutical composition, the testing result of indexs such as patient's ultrasound wave, see following table for details:
| Project name | Obey Koryo of the present invention liver beneficial pharmaceutical composition provirus property liver cirrhosis | Obey viral liver cirrhosis behind the liver beneficial pharmaceutical composition of Koryo of the present invention |
| The right liver of liver (front and back size) left side liver | 132 87 | 126 77 |
| Liver structure echo | Irregular, echo group arranged | Irregular, echo group arranged |
| Liver echo | Echo is improved | Echo is improved |
| The right branch of portal vein arteries and veins | 11 | 11 |
| Portal venous flow cm/ second | 17.1 | 21 |
| The spleen area | 67cm 2 | 58.5cm 2 |
| Spleen structure echo | Neatly, even | Neatly, even |
| The abdominal cavity free liquid | A small amount of around liver, the spleen | A small amount of around liver, the spleen |
Treat after 2 months, the liver size is dwindled, and liver parenchyma density reduces.
Conclusion: the Portal system of patient with liver cirrhosis and spleen structure can change, this can show in the combined echocardiography inspection, the patient's sick time length and the order of severity are depended in this variation, and promptly the blood vessel profile loses the degree of supporting (distortion, coarse), the change of portal system blood flow wave spectrum characteristics etc.2 liver cirrhosis patients of taking the Koryo liver beneficial pharmaceutical composition are carried out the combined echocardiography detection, show that the echo image is clearly better, portal venous flow is obviously accelerated, and liver, spleen size are dwindled.
Four, the effect of clinical treatment:
In 32 routine patients, 22 examples of being in hospital, outpatient service 10 examples, wherein male 29 examples, women 3 examples, retired worker's 7 examples, cadre's 6 examples, resident's 10 examples, peasant's 9 examples.Minimum 38 years old of age, maximum 75 years old.There are 28 examples to cause among the 32 routine patients, alcoholic cirrhosis, each 2 example of fatty liver liver cirrhosis by " hepatitis B "." liver cirrhosis " time of finding is the shortest 4 months, the longest 15 years, and every patient wherein has 3 examples to make " splenectomy " with " ascites ", all patients all through repeatedly, permanent treatment.
1, indicator-specific statistics: 32 routine patients, remove 3 and made " splenectomy ", all the other all have in various degree the liver function damage and hypersplenism, esophageal-gastric at the bottom of cirsoid performance, there are several physiochemical indices of 15 routine renal functioies unusual, blood urea nitrogen, the sweet rising of flesh; the urine routine all has albuminuria, and wherein 2 examples have cast.Lab testing all has albumin, WBC, RBC, hemoglobin, platelet count to reduce.Patients clinical shows all poor, weak, the two lower limb of spiritedness edema in various degree, ascites, dental haemorrhage.It is the case that one group of typical liver function is lost compensatory and hypersplenism.
2, treatment situation: no matter 32 routine patients are in hospital and the outpatient because of the history of long-term treatment is arranged, and other medicine of having stopped using has only been obeyed Koryo of the present invention liver beneficial pharmaceutical composition.Measure outside body weight, the abdominal circumference every day during treating, and strictness is filled in a form and performed corresponding progress note.
3, therapeutic outcome: 32 routine patients 5 pattern of syndrome are arranged,, have 4 patients that loose stool is arranged, stool every day 2-4 time, i.e. liver and spleen blood stasis defect type in first week of taking medicine; There is 5 patients sense vexed, " have and detest the oil sensation ", stomach discomfort.All the other patients have no adverse reaction.In second week, patient does not all have sense of discomfort.In the 3rd week, it is in high spirits that patient feels, appetite increases.There are 2 people's gingival hemorrhages obviously to reduce.Treat half a year, the patient effect is better, and existing 15 people are clearly better.Particularly Xu so-and-so, effect is obvious, and is conscious in high spirits, appetite increases, and sleep, the defeated albumin time obviously reduces (former defeated weekly albumin was failed once in existing one month).The check B ultrasonic: the flat abdominal cavity that crouches, ascites be by original 70mm, drops to reach 2mm, and the more preceding minimizing of liver luminous point, liver is got back to original size.
In sum, this Koryo liver beneficial pharmaceutical composition can be treated chronic hepatitiss such as viral hepatitis, hepatic ascites, alcoholic liver, fatty liver, liver cirrhosis effectively, and can reduce fat in liver and the blood, the effect of maintenance liver, and can strengthen the microcirculation that liver blood flows the regulating liver-QI parenchyma, reduce internal organs congestion, accelerate liver blood flow speed, the development of prevention liver chronic fibrosis slows down the fibrosis process, promotes liver cell regeneration.
Claims (4)
1. a liver beneficial pharmaceutical composition that is used for the treatment of chronic hepatitis is characterized in that the crude drug composition is by weight: 8 parts to 10 parts of Radix Ginsengs, 10 parts to 14 parts of the Radix Paeoniae Albas, 10 parts to 14 parts of Ningxia Fructus Lyciis, 7 parts to 8 parts of Rhizoma Chuanxiongs, 7 parts to 8 parts of Rhizoma Cyperis, 16 parts to 33 parts of Fructus Perillae oil, 22 parts to 28 parts of mushrooms, 8 parts to 10 parts of semen juglandiss, 8 parts to 12 parts of Ovum Gallus domesticus Flavuss, 220 parts to 280 parts of duck meats, 2 parts to 5 parts in Radix Glycyrrhizae.
2. a liver beneficial pharmaceutical composition that is used for the treatment of chronic hepatitis is characterized in that the crude drug composition is by weight: 9 parts of Radix Ginsengs, 11 parts of the Radix Paeoniae Albas, 13 parts of Ningxia Fructus Lyciis, 8 parts of Rhizoma Chuanxiongs, 8 parts of Rhizoma Cyperis, 31 parts of Fructus Perillae oil, 28 parts of mushrooms, 9 parts of semen juglandiss, 10 parts of Ovum Gallus domesticus Flavuss, 260 parts of duck meats, 3 parts in Radix Glycyrrhizae.
3. the production method of a liver beneficial pharmaceutical composition according to claim 1 and 2, it is characterized in that being undertaken by following step: at first Radix Ginseng, Rhizoma Cyperi, semen juglandis, the Ovum Gallus domesticus Flavus with requirement is ground into fine powder, the duck meat of requirement is rubbed, the Fructus Perillae oil that adds requirement, mix with above-mentioned fine powder, place jar, add a cover water proof with moderate heat stew open in water after 0.5 hour to 2 hours, cold drying and pulverize and obtain medicated powder then; All the other Radix Paeoniae Albas, Ningxia Fructus Lycii, Rhizoma Chuanxiong, mushroom, each medicinal water extraction of Radix Glycyrrhizae 3 times are filtered, and filtrate is condensed into the extractum that relative density is 1.32-1.34, at last extractum and above-mentioned medicated powder mixing is obtained the liver beneficial pharmaceutical composition semi-finished product.
4. the production method of liver beneficial pharmaceutical composition according to claim 3 is characterized in that liver beneficial pharmaceutical composition semi-finished product corning or makes powder obtaining the liver beneficial pharmaceutical composition finished product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005102007379A CN100384458C (en) | 2005-11-25 | 2005-11-25 | Liver beneficial pharmaceutical composition and method for preparing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005102007379A CN100384458C (en) | 2005-11-25 | 2005-11-25 | Liver beneficial pharmaceutical composition and method for preparing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1827139A CN1827139A (en) | 2006-09-06 |
| CN100384458C true CN100384458C (en) | 2008-04-30 |
Family
ID=36945821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005102007379A Active CN100384458C (en) | 2005-11-25 | 2005-11-25 | Liver beneficial pharmaceutical composition and method for preparing the same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100384458C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104069173A (en) * | 2014-07-15 | 2014-10-01 | 延边利孚生物科技有限公司 | Medicine composition for treating hepatic diseases and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104524086B (en) * | 2014-12-09 | 2018-02-16 | 青岛农业大学 | A kind of Chinese medicine composition for being used to treat Cynoglossus semilaevis Ascites Disease |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1090183A (en) * | 1993-01-28 | 1994-08-03 | 奥忠友 | Artemisia scoparia and ginseng pellet for mourishing liver and method for production thereof |
-
2005
- 2005-11-25 CN CNB2005102007379A patent/CN100384458C/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1090183A (en) * | 1993-01-28 | 1994-08-03 | 奥忠友 | Artemisia scoparia and ginseng pellet for mourishing liver and method for production thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104069173A (en) * | 2014-07-15 | 2014-10-01 | 延边利孚生物科技有限公司 | Medicine composition for treating hepatic diseases and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1827139A (en) | 2006-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102772671B (en) | Traditional Chinese medicine composition for treating deficiency of both qi and yin of sicca syndrome | |
| CN103007206A (en) | Oral liquid for treating chronic atrophic gastritis | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN101537159B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN100384458C (en) | Liver beneficial pharmaceutical composition and method for preparing the same | |
| CN104826015A (en) | Traditional Chinese medicine with effects of invigorating kidneys and replenishing essence, dispersing blood stasis and dredging collaterals as well as softening veins and eliminating speckles | |
| CN102872313B (en) | Traditional Chinese medicine qi-tonifying and kidney-nourishing decoction for treating henoch-schonlein purpura nephritis | |
| CN102178759B (en) | Traditional Chinese medicine composition for treating rheumatism and preparation method of composition | |
| CN101152532B (en) | Traditional Chinese medicine preparations for treating gynecology disease | |
| CN102657827A (en) | Traditional Chinese medicine used for treating liver and gall diseases and preparation method thereof | |
| CN100540030C (en) | A kind of topical agent for the treatment of dysmenorrhes | |
| CN103638456A (en) | Traditional Chinese medicine for treating liver cirrhosis and preparation method for same | |
| CN102552767B (en) | Traditional Chinese medicine for treating kidney stone, preparation method and administration mode | |
| CN105902872A (en) | Traditional Chinese medicine composition for treating edema | |
| CN109528979A (en) | A kind of composition and its preparation method and application for treating Sjogren syndrome and syndrome of yin deficiency and blood stasis | |
| CN103251902A (en) | External Chinese medicine for treating infantile digestive diseases as well as preparation method and application of external Chinese medicine | |
| CN115624582B (en) | New prescription for treating knee pain and preparation method and application thereof | |
| CN103110760B (en) | A kind of Chinese medicine composition for the treatment of tumor and preparation method thereof | |
| CN102198239B (en) | Medicament for treating cervical erosion | |
| CN101693096A (en) | Medicament for treating liver cancer and preparation method thereof | |
| CN100333780C (en) | Chinese medicine for antisenility and its preparation method | |
| CN104208184B (en) | A kind of pharmaceutical composition treating benign prostatic hyperplasia | |
| CN105497637B (en) | A kind of Chinese materia medica preparation for treating metabolic syndrome | |
| CN116370592A (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver fibrosis as well as preparation method and application thereof | |
| CN103251669B (en) | Anti-hepatic fibrosis drug composite |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160511 Address after: 518000 Guangdong city of Shenzhen province Qianhai Shenzhen Hong Kong cooperation zone before Bay Road No. 1 building 201 room A (located in Shenzhen Qianhai Business Secretary limited) the actual place of business of Shenzhen Nanshan Nanhai Avenue sunshine Huayi Building 1 4 floor 4F, 4G-02 Patentee after: Shenzhen Fu Fu Biotechnology Co., Ltd. Address before: 830002 room 2301, Rongsheng garden, 35 Xinmin Road, the Xinjiang Uygur Autonomous Region, Urumqi Patentee before: Lv Yunyi |